Feasibility of 18F-fluoromisonidazole kinetic modeling in head and neck cancer using shortened acquisition times

M Grkovski, J Schwartz, M Gönen… - Journal of Nuclear …, 2016 - Soc Nuclear Med
18F-fluoromisonidazole dynamic PET (dPET) is used to identify tumor hypoxia
noninvasively. Its routine clinical implementation, however, has been hampered by the long …

Multiparametric imaging of tumor hypoxia and perfusion with 18F-fluoromisonidazole dynamic PET in head and neck cancer

M Grkovski, H Schöder, NY Lee, SD Carlin… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Tumor hypoxia and perfusion are independent prognostic indicators of patient outcome. We
developed the methodology for and investigated the utility of multiparametric imaging of …

Pharmacokinetic analysis of hypoxia 18F-fluoromisonidazole dynamic PET in head and neck cancer

W Wang, NY Lee, JC Georgi… - Journal of Nuclear …, 2010 - Soc Nuclear Med
This study used pharmacokinetic analysis of 18F-labeled fluoromisonidazole (18F-FMISO)
dynamic PET to assist the identification of regional tumor hypoxia and to investigate the …

Pharmacokinetic analysis of dynamic 18F-fluoromisonidazole PET data in non–small cell lung cancer

J Schwartz, M Grkovski, A Rimner… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Hypoxic tumors exhibit increased resistance to radiation, chemical, and immune therapies.
18F-fluoromisonidazole (18F-FMISO) PET is a noninvasive, quantitative imaging technique …

Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer

M Grkovski, NY Lee, H Schöder, SD Carlin… - European journal of …, 2017 - Springer
Purpose There is growing recognition that biologic features of the tumor microenvironment
affect the response to cancer therapies and the outcome of cancer patients. In head and …

[HTML][HTML] Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer

D Thorwarth, SM Eschmann, J Scheiderbauer… - BMC cancer, 2005 - Springer
Background Hypoxia compromises local control in patients with head-and-neck cancer
(HNC). In order to determine the value of [18 F]-fluoromisonidazole (Fmiso) with regard to …

Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy

SM Eschmann, F Paulsen, M Reimold… - Journal of nuclear …, 2005 - Soc Nuclear Med
In radiotherapy of head and neck cancer (HNC) and non-small cell lung cancer (NSCLC),
hypoxia is known to be an important prognostic factor for long-term survival and local tumor …

High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer

S Okamoto, T Shiga, K Yasuda, YM Ito… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Tumor hypoxia is well known to be radiation resistant. 18F-fluoromisonidazole (18F-FMISO)
PET has been used for noninvasive evaluation of hypoxia. Quantitative evaluation of 18F …

Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging

W Wang, JC Georgi, SA Nehmeh… - Physics in Medicine …, 2009 - iopscience.iop.org
This paper systematically evaluates a pharmacokinetic compartmental model for identifying
tumor hypoxia using dynamic positron emission tomography (PET) imaging with 18 F …

Comparison of DCE‐MRI kinetic parameters and FMISO‐PET uptake parameters in head and neck cancer patients

U Simoncic, S Leibfarth, S Welz, N Schwenzer… - Medical …, 2017 - Wiley Online Library
Purpose Tumor hypoxia is a major cause of radiation resistance, often present in various
solid tumors. Dynamic [18F]‐fluoromisonidazole (FMISO) PET imaging is able to reliably …